Rosemary Oil for Hair Growth: The Evidence vs Minoxidil

Social media platforms have turned scalp oiling into one of the fastest-growing hair-wellness trends of the decade. At the center of this movement is rosemary oil (Rosmarinus officinalis / Salvia rosmarinus), frequently marketed as a natural, non-prescription alternative to pharmaceutical hair-loss medications that can match the performance of minoxidil without synthetic side effects.

The viral claim traces to a single 2015 randomized comparative trial of 100 adults with androgenetic alopecia, where rosemary oil matched minoxidil 2% on hair count increase at 6 months with significantly less scalp itching. However, neither group showed significant growth at the 3-month mark, and no independent second trial has replicated these head-to-head results. Furthermore, a rigorous 2025 Canadian Delphi consensus panel of 11 hair-loss specialist physicians evaluated 45 interventions and placed rosemary oil on its explicit "not recommended" list, while endorsing evidence-backed therapies like minoxidil, finasteride, dutasteride, PRP, and microneedling. A 2025 Bayesian network meta-analysis of 24 trials confirmed that conventional pharmaceutical therapies consistently outperform over-the-counter botanicals on 24-week hair density. If you choose to try rosemary oil as an adjunct, it must be properly diluted in a carrier oil and patch-tested first, because concentrated essential oils are potent contact allergens that can cause contact dermatitis and paradoxical shedding.

To make an informed decision between botanical remedies and medical therapeutics, consumers must understand what the clinical trial data actually demonstrated, how rosemary constituents operate mechanistically, what recent specialist guidelines conclude, and the practical safety boundaries of essential oil application.

---

What the One Head-to-Head Trial (Panahi 2015) Actually Found

Almost every social media video, wellness article, and retail product claim asserting that rosemary oil "works as well as minoxidil" originates from a single human study published in 2015 by Panahi and colleagues in the journal Skinmed.

Panahi et al. (2015) Trial Design & Endpoints:
┌─────────────────────────────────────────────────────────────────────────────┐
│ Population: 100 Adults with Androgenetic Alopecia (50 per arm)              │
│ Duration: 6 Months (Assessments at Baseline, Month 3, Month 6)              │
├────────────────────────────────────────┬────────────────────────────────────┤
│ Arm A: Rosemary Oil Lotion (n=50)      │ Arm B: Minoxidil Solution 2% (n=50)│
├────────────────────────────────────────┼────────────────────────────────────┤
│ Month 3: No significant change vs base │ Month 3: No significant change     │
│ Month 6: Significant count increase    │ Month 6: Significant count increase│
│ Between-Group Difference at Month 6:   │ No statistically significant diff  │
│ Scalp Itching (Pruritus):              │ Significantly higher in Minoxidil  │
└────────────────────────────────────────┴────────────────────────────────────┘

Study Structure and Subject Population

The trial enrolled 100 adult patients diagnosed with androgenetic alopecia (pattern hair loss). Participants were randomized into two equal groups of 50:

1. Rosemary Oil Arm: Received a standardized rosemary oil formulation (1 mL applied to the scalp twice daily).
2. Minoxidil 2% Arm: Received standard over-the-counter minoxidil 2% topical solution (1 mL applied twice daily).

Standardized microphotographs of a defined scalp zone were taken at baseline, after 3 months, and after 6 months of daily application to quantify total hair counts.

Key Efficacy Findings and the 3-Month Null Result

The trial produced several critical findings that are frequently omitted in viral marketing:

• The 3-Month Null Finding: At the 3-month evaluation point, neither the rosemary oil group nor the minoxidil 2% group showed a statistically significant increase in hair count compared to their respective baselines. Hair follicle cycling operates on biological time scales, meaning rapid 30-day or 60-day transformations advertised online have no clinical foundation.
• The 6-Month Outcome: At 6 months, both groups demonstrated a statistically significant increase in hair counts compared to baseline. Crucially, there was no statistically significant difference in mean hair count gain between the rosemary oil group and the minoxidil 2% group.
• Secondary Adverse Effects: Scalp itching (pruritus) was reported in both groups as an adverse event. However, pruritus was significantly more frequent in the minoxidil 2% group compared to the rosemary oil group at both the 3-month and 6-month assessments. This difference was largely attributed to the propylene glycol vehicle commonly used in standard topical minoxidil solutions, which is a known skin irritant.

Critical Limitations of the 2015 Trial

While the Panahi trial is a legitimate randomized comparative study, dermatologists and clinical researchers emphasize several structural caveats:

1. Minoxidil 2% vs 5% Comparator: The trial compared rosemary oil against minoxidil 2%, the lower-strength formulation traditionally formulated for women. For male androgenetic alopecia and modern female pattern hair loss protocols, minoxidil 5% topical solution or foam is the standard clinical benchmark, which delivers substantially higher follicular stimulation. The study did not test rosemary oil against 5% minoxidil or oral minoxidil.
2. No Vehicle / Placebo Control Arm: Because the trial only compared rosemary against minoxidil 2% without an inactive vehicle control arm, it is impossible to completely separate active pharmacological stimulation from the mechanical stimulation of twice-daily scalp massage, which itself has been shown in small studies to modestly improve localized blood flow.
3. Single-Center and Lack of Replication: In the eleven years since its publication, no major independent research group has replicated this head-to-head trial in a larger, multi-center cohort. In evidence-based medicine, a single trial of 100 individuals represents preliminary, hypothesis-generating data rather than settled clinical proof.

---

How Rosemary Might Work: Circulation and Anti-Inflammatory Evidence

Botanical extracts contain complex mixtures of phytochemicals. Rather than acting as a single purified drug molecule, rosemary essential oil contains several bioactive diterpenes and phenolic compounds that exhibit relevant biological activities in laboratory models.

Key Bioactive Constituents in Rosmarinus officinalis:
┌───────────────────┬─────────────────────────────────────────────────────────┐
│ Constituent       │ Primary Laboratory Mechanism                            │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Carnosic Acid     │ Potent antioxidant; Nrf2 pathway activator; modulates   │
│                   │ inflammatory cytokines (IL-1β, TNF-α) in skin models    │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Rosmarinic Acid   │ Free radical scavenger; inhibits lipid peroxidation;    │
│                   │ modulates microvascular inflammation                    │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ 1,8-Cineole       │ Terpene penetration enhancer; enhances cutaneous        │
│ (Eucalyptol)      │ microcirculation; antimicrobial against scalp flora     │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Carnosol          │ Downregulates 5α-reductase expression in cell assays;   │
│                   │ suppresses NF-κB inflammatory signaling                 │
└───────────────────┴─────────────────────────────────────────────────────────┘

1. Modulation of Cutaneous Microcirculation

One of the primary proposed mechanisms is the enhancement of local microvascular blood flow around hair follicles. The monoterpene constituents (primarily 1,8-cineole and alpha-pinene) produce mild local vasodilation upon topical contact. By improving capillary perfusion in the dermal papilla, rosemary application may facilitate the delivery of oxygen and systemic nutrients to actively metabolizing follicular keratinocytes, mimicking some of the vasodilatory characteristics of minoxidil.

2. Antioxidant and Anti-Inflammatory Action (Carnosic Acid)

Follicular micro-inflammation and oxidative stress play significant roles in the pathogenesis of androgenetic alopecia and telogen effluvium. A comprehensive 2025 review in Planta Medica highlighted carnosic acid, a major abietane diterpene in rosemary, as a key therapeutic candidate. In preclinical models, carnosic acid activates the Nrf2/ARE antioxidant signaling pathway, shielding follicular cells from reactive oxygen species (ROS) induced by dihydrotestosterone (DHT) and environmental stressors. Furthermore, it suppresses pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) that trigger premature follicular transition into the catagen (involution) phase.

3. Mild 5-Alpha Reductase Modulation in Vitro

In laboratory cell cultures, crude rosemary extract and isolated carnosol have demonstrated weak inhibitory activity against the 5-alpha reductase enzyme, which converts testosterone into DHT. However, this in vitro enzymatic inhibition is several orders of magnitude weaker than pharmaceutical 5-alpha reductase inhibitors like finasteride or dutasteride. Topical rosemary oil cannot substantially lower follicular DHT levels in a living human scalp in the manner of approved anti-androgenic medications. For readers exploring how systemic and topical medications suppress DHT, see our evidence-based guide to androgenetic alopecia treatment.

---

What 2025 Guidelines and a Network Meta-Analysis Say About Rosemary Oil

When medical specialty organizations synthesize the entire body of clinical literature to create treatment guidelines, isolated viral remedies are evaluated against rigorous grading frameworks.

Evidence Hierarchy for Androgenetic Alopecia Interventions:
┌─────────────────────────────────────────────────────────────────────────────┐
│ 1. RECOMMENDED FIRST-LINE (High-Quality Multi-Center RCTs / Meta-Analyses)  │
│    • Oral Finasteride (1 mg/day) & Oral Dutasteride (0.5 mg/day)            │
│    • Topical Minoxidil (5% Foam / Solution) & Low-Dose Oral Minoxidil       │
│    • Topical Finasteride & In-Clinic PRP / Scalp Microneedling Adjuncts    │
├─────────────────────────────────────────────────────────────────────────────┤
│ 2. NEAR-CONSENSUS / CONDITIONAL (Moderate Evidence Base)                   │
│    • Low-Level Laser Therapy (LLLT / Photobiomodulation 650 nm)             │
│    • Spironolactone / Cyproterone (Female Pattern Hair Loss)                 │
├─────────────────────────────────────────────────────────────────────────────┤
│ 3. NOT RECOMMENDED AS MONOTHERAPY (2025 Specialist Consensus)               │
│    • Rosemary Oil, Biotin Supplements (in non-deficient patients)           │
│    • Castor Oil, Onion Juice, Caffeine Shampoos, Stem Cell Serums          │
└─────────────────────────────────────────────────────────────────────────────┘

The 2025 Canadian Delphi Consensus on Androgenetic Alopecia

In 2025, an expert panel of 11 Canadian dermatologists and hair-loss specialists conducted a formal Delphi consensus process published in the Journal of Cutaneous Medicine and Surgery (Landells et al., 2025). The panel rigorously evaluated 45 distinct medical, surgical, and over-the-counter interventions for androgenetic alopecia:

• The Recommended Interventions (7 Interventions): The panel reached strong consensus recommending oral dutasteride, oral finasteride, topical finasteride, topical minoxidil, oral minoxidil, platelet-rich plasma (PRP), and microneedling.
• The Not-Recommended Interventions (17 Interventions): The panel placed rosemary oil directly on its list of 17 interventions not recommended for the management of androgenetic alopecia.

The rationale was straightforward: while rosemary oil has one interesting 6-month trial, the aggregate clinical evidence remains insufficient to recommend it as a primary treatment. Relying on an unproven botanical instead of starting approved therapies allows progressive follicular miniaturization to advance unchecked, resulting in irreversible hair follicle loss.

The 2025 Bayesian Network Meta-Analysis (NMA)

A 2025 comprehensive Bayesian network meta-analysis published in the Journal of Cosmetic Dermatology evaluated 24 randomized controlled trials involving conventional monotherapies and nonconventional OTC products for hair density outcomes at 24 weeks.

• Dominance of Approved Drugs: Oral dutasteride (0.5 mg/day) and oral/topical minoxidil (5%) achieved the highest Surface Under the Cumulative Ranking (SUCRA) probabilities for total hair density improvements.
• Position of Nonconventional Products: While topical rosemary oil and topical melatonin demonstrated positive trend lines compared to inactive placebos, their relative effect sizes and statistical certainty remained substantially below those of standard FDA-cleared and approved pharmaceutical therapies.

For individuals experiencing diffuse shedding rather than genetic pattern miniaturization, consult our comprehensive review of telogen effluvium causes and recovery timeline to avoid misapplying androgen-focused remedies to stress-related shedding.

---

Safety: Essential Oils Are Allergens (Dilution, Patch Testing, Pregnancy Caution)

One of the most dangerous misconceptions in consumer wellness is the assumption that "natural" products cannot cause adverse reactions. In dermatological practice, essential oils are among the most frequent culprits in allergic contact dermatitis of the scalp and neck.

Step-by-Step 48-Hour Patch Test Protocol:
┌─────────────────────────────────────────────────────────────────────────────┐
│ 1. PREPARE THE DILUTION:                                                    │
│    Mix 1 to 2 drops of 100% pure rosemary essential oil into 1 teaspoon     │
│    (5 mL) of a non-comedogenic carrier oil (e.g., jojoba, squalane, argan). │
│    Never apply neat (undiluted) essential oil directly to skin.             │
├─────────────────────────────────────────────────────────────────────────────┤
│ 2. APPLICATION:                                                             │
│    Apply a dime-sized amount of the diluted mixture to a clean test site:   │
│    the inner forearm or the skin immediately behind the ear (post-auricular)│
├─────────────────────────────────────────────────────────────────────────────┤
│ 3. OBSERVATION WINDOW:                                                      │
│    Leave the area undisturbed and unwashed for 24 to 48 hours.              │
│    Check for: erythema (redness), pruritus (itching), burning, or papules.  │
├─────────────────────────────────────────────────────────────────────────────┤
│ 4. INTERPRETATION:                                                          │
│    • CLEAR SKIN: Proceed with cautious scalp application 2–3x weekly.       │
│    • REDNESS / ITCHING / BUMP: Do NOT apply to the scalp. Wash thoroughly.  │
└─────────────────────────────────────────────────────────────────────────────┘

1. Contact Dermatitis and the Paradoxical Shedding Risk

Pure rosemary essential oil contains concentrated terpenes, including camphor, pinene, limonene, and linalool. When exposed to air and light, these monoterpenes oxidize into highly sensitizing hydroperoxides.

• The Scalp Barrier: The scalp is highly vascularized and absorbs topical formulations rapidly. Applying undiluted ("neat") rosemary oil can trigger acute irritant contact dermatitis or cell-mediated allergic contact dermatitis.
• Paradoxical Telogen Effluvium: Severe scalp inflammation, weeping eczema, or crusting directly impairs hair follicle function. An acute allergic reaction on the scalp frequently triggers secondary telogen effluvium, accelerating hair shedding rather than preventing it.
• Therapeutic Sensitization Precedent: In clinical dermatology, potent contact sensitizers (such as diphenylcyclopropenone / DPCP) are intentionally used to provoke allergic contact dermatitis in the treatment of severe alopecia areata. Applying essential oils indiscriminately risks inducing unintentional sensitization.

2. Proper Dilution Guidelines

If you choose to use rosemary oil, you must formulate it within safe dermatological concentration boundaries:

• Concentration: Use a 1% to 2% dilution. This equates to roughly 3 to 6 drops of essential oil per 1 fluid ounce (30 mL) of carrier oil.
• Carrier Oil Selection: Choose lightweight, non-comedogenic carrier oils that do not promote Malassezia yeast overgrowth on the scalp:
  • Jojoba Oil: Mimics natural human sebum; chemically stable.
  • Squalane (Plant-Derived): Highly stable, non-greasy, non-comedogenic.
  • Argan Oil or Caprylic/Capric Triglycerides (MCT Oil): Well tolerated for dry scalps.
• Avoid Heavy Comedogenic Oils: Avoid using thick coconut oil or pure olive oil if you have a history of seborrheic dermatitis, dandruff, or acne, as heavy saturated lipids feed Malassezia furfur and exacerbate scalp flaking.

3. Pregnancy and Breastfeeding Warnings

Pregnant or nursing individuals must exercise strict caution with essential oils:

• Emmenagogue Properties: Historically, high doses of rosemary extract have been recognized to possess mild emmenagogue properties (uterine stimulating potential). While systemic absorption from a properly diluted 1% topical scalp lotion is low, safety has not been established in clinical trials for pregnant or lactating populations.
• Neurological Caution: High concentrations of camphor-containing essential oils are contraindicated in individuals with active seizure disorders or epilepsy, as systemic camphor absorption can lower the seizure threshold.

---

Related Viral Oils Ranked: Peppermint, Castor, Pumpkin Seed, Caffeine

Rosemary is not the only botanical oil promoted for hair regrowth. Comparing the clinical evidence across popular natural remedies reveals a wide disparity between laboratory hype and human clinical validation.

Evidence Ranking of Viral Hair Growth Remedies:
┌───────────────────┬────────────────────┬────────────────────────────────────┐
│ Treatment         │ Evidence Level     │ Key Clinical Findings              │
├───────────────────┼────────────────────┼────────────────────────────────────┤
│ Rosemary Oil      │ Human RCT (n=100)  │ Matched 2% minoxidil at 6 months;  │
│                   │ Small, unblinded   │ no effect at 3 months; unverified  │
├───────────────────┼────────────────────┼────────────────────────────────────┤
│ Pumpkin Seed Oil  │ Human RCT (n=76)   │ 400 mg oral daily: 40% hair count  │
│ (Oral Supplement) │ Double-blind       │ increase vs 10% placebo at 24 wks  │
├───────────────────┼────────────────────┼────────────────────────────────────┤
│ Peppermint Oil    │ Animal Data Only   │ 3% topical promoted mouse hair in  │
│                   │ (Mouse models)     │ 4-wk trial; zero human AGA trials  │
├───────────────────┼────────────────────┼────────────────────────────────────┤
│ Castor Oil        │ Cosmetic / Anecdote│ Ricinoleic acid; increases gloss & │
│ (Ricinoleic Acid) │ No Controlled RCTs │ coat; no human follicle regrowth   │
├───────────────────┼────────────────────┼────────────────────────────────────┤
│ Topical Caffeine  │ Small Pilot RCTs   │ Weak 5α-reductase modulation;      │
│                   │ In vitro models    │ shampoo contact time is too short  │
└───────────────────┴────────────────────┴────────────────────────────────────┘

1. Peppermint Oil: The "Better Than Minoxidil" Mouse Study

A frequent claim on social media is that peppermint oil is "superior to minoxidil." This claim originates entirely from a 2014 study published in Toxicological Research by Oh et al.

• The Study Design: Researchers applied 3% peppermint oil, saline, jojoba oil, or 3% minoxidil to shaved C57BL/6 laboratory mice for 4 weeks.
• The Result: Peppermint oil promoted rapid anagen hair growth and increased dermal thickness in mice, outperforming 3% minoxidil in this specific animal model.
• The Reality: Rodent hair biology differs fundamentally from human androgenetic alopecia. Mice do not develop human pattern baldness driven by androgen receptor sensitivity. There has never been a published human randomized controlled trial testing peppermint oil for androgenetic alopecia.

2. Pumpkin Seed Oil: The Oral Human Trial

Pumpkin seed oil (Cucurbita pepo) has legitimate human trial data, albeit through oral supplementation rather than topical oiling.

• The 2014 Study: In a double-blind, placebo-controlled trial of 76 men with mild-to-moderate androgenetic alopecia, participants took 400 mg of oral pumpkin seed oil daily for 24 weeks.
• The Result: The treatment group showed a mean 40% increase in hair count compared to a 10% increase in the placebo group.
• Mechanism: Pumpkin seed oil contains delta-7-sterols and phytosterols that demonstrate mild 5-alpha reductase competitive antagonism. It represents one of the few botanical supplements with randomized, double-blind human evidence, reviewed in detail by the Baylor University Medical Center CAM review.

3. Castor Oil: Heavy Conditioning Without Follicular Regrowth

Castor oil (Ricinus communis) is rich in ricinoleic acid, a unique fatty acid that activates prostaglandin E2 (PGE2) receptors.

• The Reality: While castor oil is an exceptional hair shaft conditioner—coating the cuticle, reducing friction, and imparting cosmetic shine—there are zero human clinical trials demonstrating that topical castor oil stimulates miniaturized hair follicles to regrow.
• Safety Warning: Applying heavy castor oil to the scalp can lead to acute hair felting (a severe, irreversible tangling of the hair mat that requires shaving) and folliculitis. For a parallel look at how castor oil and botanical peptides perform in eyelash products, read our eyelash growth serum evidence review.

4. Topical Caffeine Formulations

Caffeine is a water-soluble methylxanthine that readily penetrates follicular infundibula and counteracts testosterone-induced follicle suppression in human ex vivo culture models. However, when delivered in rinse-off shampoos, contact time (typically 1 to 2 minutes) is insufficient to achieve therapeutic follicular drug concentrations. Leave-on topical serums have shown modest non-inferiority in small pilot studies, but remain secondary adjuncts.

For individuals suffering from hairline recession caused by tight braids, extensions, or ponytails, botanical oils will not reverse mechanical tension damage; refer to our clinical review on traction alopecia treatment and prevention.

---

Comparison: Rosemary Oil vs Approved Medical Therapies

To help patients and consumers navigate their options objectively, the following decision table contrasts rosemary oil against established medical and procedural therapies.

---

The Clinical Verdict: How to Approach Rosemary Oil

If you are evaluating rosemary oil for hair growth, dermatologists recommend following these evidence-based principles:

1. Do Not Delay Proven Medical Therapy for Active Loss: If you have noticeable thinning, widening of your part, or a receding hairline, androgenetic alopecia is actively progressing. Waiting 6 to 12 months on a viral oil allows hair follicles to permanently miniaturize. Establish a foundation with proven, guideline-recommended therapies (minoxidil, finasteride/dutasteride, or LLLT) first.
2. Use Only as a Secondary Adjunct: If you wish to incorporate rosemary oil, treat it as a supportive scalp-conditioning adjunct rather than your sole defense against genetic hair loss.
3. Always Dilute and Patch Test: Never apply pure essential oil to your scalp. Dilute 3 to 5 drops into 1 ounce of squalane or jojoba oil, perform a 48-hour patch test behind your ear, and discontinue immediately if you experience redness, itching, or increased shedding.

---

FAQ

How long does rosemary oil take to work on hair?

In the single published randomized clinical trial (Panahi 2015), neither rosemary oil nor minoxidil 2% produced any statistically significant increase in hair counts at the 3-month mark. Significant improvements were only measurable after 6 full months of continuous twice-daily application. Consumers expecting visible results within 4 to 8 weeks are likely observing cosmetic conditioning or seasonal shedding fluctuations rather than active follicular regrowth.

Can I use rosemary oil together with minoxidil?

Yes, but you should not apply them at the exact same moment. If you use topical minoxidil (especially liquid formulations containing alcohol and propylene glycol), apply minoxidil to a dry, clean scalp and allow it to absorb fully for at least 2 to 4 hours before applying any diluted oil. Applying thick oils immediately before minoxidil can create a lipid barrier that impairs minoxidil absorption, while applying essential oils over irritated skin can increase the risk of contact dermatitis.

Is rosemary oil safe during pregnancy or while breastfeeding?

Concentrated rosemary essential oil should be avoided or used only with explicit obstetrician approval during pregnancy. Rosemary has historical emmenagogue properties (potential to stimulate uterine contractions) in high concentrations. While systemic absorption from a properly diluted 1% topical scalp lotion is low, no controlled clinical trials have evaluated its safety during pregnancy or lactation. In contrast, approved pharmaceutical hair-loss drugs like finasteride, dutasteride, and oral minoxidil are strictly contraindicated during pregnancy.

---

Sources

• Panahi, Y., et al. "Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial." Skinmed, vol. 13, no. 1, 2015, pp. 15-21. PubMed: https://pubmed.ncbi.nlm.nih.gov/25842469/
• Landells, I., et al. "A Canadian Consensus on Androgenetic Alopecia: Diagnosis and Treatment." Journal of Cutaneous Medicine and Surgery, vol. 29, no. 5 Suppl, 2025, pp. 5S-14S. PubMed: https://pubmed.ncbi.nlm.nih.gov/40986632/
• "Relative efficacy of conventional monotherapies and select nonconventional over-the-counter products for male androgenetic alopecia: A Bayesian network meta-analysis." Journal of Cosmetic Dermatology, vol. 24, no. 10, 2025, p. e70483. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12498493/
• "Therapeutic Potential of Carnosic Acid in Alopecia: A Mechanistic Perspective." Planta Medica, 2025. PubMed: https://pubmed.ncbi.nlm.nih.gov/40780265/
• "Review on natural remedies for hair growth promotion with a focus on rosemary (Rosmarinus officinalis L.)." Dermatology Reports, 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/41630600/
• Oh, J.Y., Park, M.A., and Kim, Y.C. "Peppermint Oil Promotes Hair Growth without Toxic Signs." Toxicological Research, vol. 30, no. 4, 2014, pp. 297-304. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4289931/
• Cho, Y.H., et al. "Effect of Pumpkin Seed Oil on Hair Growth in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled Trial." Evidence-Based Complementary and Alternative Medicine, 2014. PubMed: https://pubmed.ncbi.nlm.nih.gov/24864154/
• "Complementary and alternative supplements: a review of dermatologic effectiveness for androgenetic alopecia." Proceedings (Baylor University Medical Center), vol. 37, no. 1, 2024, pp. 111-117. PubMed: https://pubmed.ncbi.nlm.nih.gov/38174012/
• "A Qualitative Review of Misinformation on Alopecia." Skin Appendage Disorders, vol. 11, no. 2, 2025, pp. 182-185. PubMed: https://pubmed.ncbi.nlm.nih.gov/40176994/